Literature DB >> 16892011

Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder.

Wu Yin1, Ni Chen, Yutao Zhang, Hao Zeng, Xueqin Chen, Yongtao He, Xiaojie Wang, Qiao Zhou.   

Abstract

The caspase family proteases are key proapoptotic proteins while the inhibitor of apoptosis proteins (IAP) prevent apoptosis by antagonizing the caspases or other key proapoptotic proteins. Limited studies of IAPs suggested their deregulation contributed to urothelial neoplasia. However, the expression status and biologic or prognostic significance of the caspase and IAP family proteins in urothelial neoplasms is not clear. In the present study, we first systematically evaluated the expression profile of the major apoptosis regulators, including caspases (CASP3, 6, 7, 8, 9, 10, and 14), IAPs (survivin/BIRC5, CIAP1, CIAP2, XIAP, and LIVIN), APAF1, SMAC, and BCL2, as well as proliferation markers Ki67 and PHH3, in Ta/T1 human urinary bladder urothelial carcinomas and normal urothelium samples by immunohistochemistry. The analysis showed that survivin/BIRC5 nuclear labeling index (BIRC5-N), but not cytoplasmic staining, was the only apoptotic marker which correlated significantly with tumor grade, stage, and patient outcome. We further analyzed the prognostic value of BIRC5-N in 101 Ta/T1 urinary bladder urothelial carcinomas by univariate analysis, which showed that BIRC5-N as well as the more classical prognosticators (stage, grade, and Ki67 index) were of prognostic significance. However, multivariate analysis by Cox proportional hazard regression demonstrated BIRC5-N was a stronger prognosticator than tumor grade, stage, and Ki67 labeling index. BIRC5-N index of 8% or more predicted unfavorable disease-specific survival (relative risk (RR)=6.6, 95% confidence interval=1.6-26.7, P=0.0080) as well as progression-free survival (RR=4.4, 95% confidence interval=1.3-14.6, P=0.0151). We conclude that BIRC5-N is a superior biologic and prognostic marker for Ta/T1 urothelial carcinomas of urinary bladder.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16892011     DOI: 10.1038/modpathol.3800675

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  17 in total

1.  [Prediction of tumor recurrence and progression of superficial bladder carcinoma using an artificial neural network].

Authors:  B Planz; T Deix; H P Caspers
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

2.  Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis.

Authors:  Shunzeng Lv; Ekaterina Turlova; Shigang Zhao; Huihui Kang; Mingzhi Han; Hong-Shuo Sun
Journal:  Tumour Biol       Date:  2013-10-08

3.  Livin, Survivin and Caspase 3 as early recurrence markers in non-muscle-invasive bladder cancer.

Authors:  Jianwen Wang; Xiaodong Zhang; Ping Wei; Junhui Zhang; Yinong Niu; Ning Kang; Yuxiang Zhang; Weili Zhang; Nianzeng Xing
Journal:  World J Urol       Date:  2014-03-05       Impact factor: 4.226

4.  Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.

Authors:  Johannes Breyer; Michael Gierth; Sanzhar Shalekenov; Atiqullah Aziz; Julius Schäfer; Maximilian Burger; Stefan Denzinger; Ferdinand Hofstädter; Christian Giedl; Wolfgang Otto
Journal:  World J Urol       Date:  2015-09-22       Impact factor: 4.226

5.  Expression of survivin in squamous cell carcinoma and transitional cell carcinoma of the urinary bladder: a comparative immunohistochemical study.

Authors:  Rania Makboul; Abeer E L-Refaiy M Refaiy; Fatma Ahmed Mahmoud Badary; Islam F Abdelkawi; Axel S Merseburger; Rabab Ahmed Ahmed Mohammed
Journal:  Korean J Urol       Date:  2015-01-08

6.  Ectopic expression of AP-2α transcription factor suppresses glioma progression.

Authors:  Wenjing Su; Juan Xia; Xueqin Chen; Miao Xu; Ling Nie; Ni Chen; Jing Gong; Xinglan Li; Qiao Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-11-26

7.  Prognostic significance of survivin, β-catenin and p53 expression in urothelial carcinoma.

Authors:  Serkan Senol; Asif Yildirim; Bahar Ceyran; Fatih Uruc; Ebru Zemheri; Seyma Ozkanli; Ibrahim Akalin; Ismail Ulus; Turhan Caskurlu; Abdullah Aydin
Journal:  Bosn J Basic Med Sci       Date:  2015-08-19       Impact factor: 3.363

8.  Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program.

Authors:  Anirban P Mitra; Jose E Castelao; Debra Hawes; Denice D Tsao-Wei; Xuejuan Jiang; Shan-Rong Shi; Ram H Datar; Eila C Skinner; John P Stein; Susan Groshen; Mimi C Yu; Ronald K Ross; Donald G Skinner; Victoria K Cortessis; Richard J Cote
Journal:  Cancer       Date:  2013-01-14       Impact factor: 6.860

9.  Expression of livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma.

Authors:  Li Chen; Guo-Sheng Ren; Fan Li; Shan-Quan Sun
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

10.  Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma.

Authors:  Hiroshi Kitamura; Toshihiko Torigoe; Yoshihiko Hirohashi; Hiroko Asanuma; Ryuta Inoue; Sachiyo Nishida; Toshiaki Tanaka; Naoya Masumori; Noriyuki Sato; Taiji Tsukamoto
Journal:  Virchows Arch       Date:  2012-11-20       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.